文献速递血管炎

巨细胞动脉炎中的磁共振血管造影:托珠单抗治疗巨细胞动脉炎随机对照试验结果

Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

本随机对照试验分析托珠单抗治疗巨细胞动脉炎的磁共振血管造影血管壁信号,受试者按2:1比例接受托珠单抗+糖皮质激素或安慰剂+糖皮质激素,每4周给药一次、持续52周。第12周托珠单抗组3例(33%)、安慰剂组1例(25%)血管壁信号恢复正常;第52周部分托珠单抗患者进一步改善,但三分之一仍有持续或加重的晚期血管壁强化,未出现动脉瘤或狭窄,动脉粥样硬化无增加。

要点

  • 第12周血管壁信号恢复正常者托珠单抗组3例(33%)、安慰剂组1例(25%)。
  • 第52周部分托珠单抗患者进一步改善,但三分之一存在持续或加重的晚期血管壁强化。
  • 未出现动脉瘤或狭窄,动脉粥样硬化无增加。

核心结论

  • 托珠单抗使巨细胞动脉炎在52周内获得完全临床和实验室缓解,但仅三分之一患者血管壁磁共振血管造影信号恢复正常。
  • 这些信号是否具有预后意义仍有待确定。

研究设计与样本

  • 随机对照试验,参与者按2:1比例接受托珠单抗+糖皮质激素或安慰剂+糖皮质激素,每4周给药一次,持续52周。
  • 糖皮质激素起始剂量为1 mg/kg/天,第12周减至0.1 mg/kg/天,此后减至零。
  • 初始磁共振血管造影阳性的患者在第12周和第52周接受对照磁共振血管造影检查。
  • 血管壁信号按0分(正常)至3分(强烈晚期强化)评分。
  • 共30例随机参与者,其中托珠单抗组9例、安慰剂组2例初始磁共振血管造影无血管壁强化。

主要发现

  • 第12周时,托珠单抗组9例、安慰剂组4例接受了磁共振血管造影检查(分别有9例和3例处于临床缓解)。
  • 第12周托珠单抗组3例(33%)血管壁信号恢复正常,安慰剂组1例(25%)恢复正常。
  • 第52周时部分托珠单抗患者磁共振血管造影进一步改善,但三分之一表现为持续或加重的晚期血管壁强化。
  • 未形成动脉瘤或狭窄,动脉粥样硬化无增加。

关键数值与推荐

  • 血管壁信号评分为0分(正常)至3分(强烈晚期强化)。
  • 第12周血管壁信号恢复正常:托珠单抗组3例(33%)vs 安慰剂组1例(25%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文述这些信号是否具有预后意义仍有待确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyse magnetic resonance angiographic (MRA) vessel wall signals from a randomized controlled trial of tocilizumab (TCZ) to treat GCA. METHODS: Participants were assigned in a 2:1 ratio to receive either TCZ + glucocorticoids (GCs) or placebo + GC infusions at 4-week intervals for 52 weeks. GCs were started at 1 mg/kg/day, then tapered to 0.1 mg/kg/day at week 12 and thereafter down to zero. Patients with initial positive MRA findings underwent control MRA at weeks 12 and 52. Vessel wall signals were scored from 0 (normal) to 3 (intense late enhancement). Outcomes were the number of patients with complete MRA remission at weeks 12 and 52, and changes in vasculitis score, vessel anatomy and atherosclerosis. RESULTS: Of the 30 randomized participants, nine TCZ and two placebo patients had no vessel wall enhancement on initial MRA. At week 12, MRAs were performed in nine TCZ and four placebo patients (nine and three in clinical remission, respectively). Three (33%) TCZ patients showed normalization of vessel wall signals compared with one (25%) placebo patient. At week 52, there was additional MRA improvement in some TCZ patients, but one-third showed persistent or increased late vessel wall enhancement. There was no formation of aneurysms or stenosis and no increase in atherosclerosis. CONCLUSIONS: Although TCZ resulted in complete clinical and laboratory remission of GCA over 52 weeks, MRA signals in vessel walls normalized in only one-third of patients. Whether these signals are of prognostic importance remains to be determined.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Reichenbach S, Adler S, Bonel H, et al. Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis. Rheumatology (Oxford). 2018. PMID: 29529280. doi:10.1093/rheumatology/key015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。